Analysis of enzymes to use for the modification of fucoidan.

褐藻糖胶是褐藻(海藻)中的一种多糖。ARC医疗器械公司已经开发出和 从褐藻中提取和纯化的褐藻糖胶用于手术后兽医减少粘连 发展。这非常有效，促使人们渴望开发出供人类使用的产品。这个 然而，对此的挑战是岩藻糖胶是一种极大的非均相组成的分子， 使a)难以达到医疗材料的纯度和均一性的更高标准 在人体受试者中使用，以及b)按人体试验所需的数量使用。 我们提出的解决方案是利用在海洋细菌中发现的自然产生的酶，并使用这些 生物处理酶，以调整岩藻糖胶的结构和大小，和/或合成岩藻糖胶片段，如 材料的大小和成分有更明确的定义，最终可以大量获得 高纯度。为实现这一目标而设想的途径有多个步骤，其具体目标是 建议是实现产生酶工具所需的初始和关键步骤，以使 岩藻糖胶的重塑和/或合成。 该项目的成功完成将导致生产一种新型的、一流的医疗设备的过程 用于减少手术后的粘连，这反过来将减少疼痛，痛苦，不孕不育和 普通外科手术后加拿大患者的死亡率；减少加拿大住院时间 重新入院和重新手术，这反过来将降低加拿大政府和 纳税人；并在加拿大创造科学、制造和销售就业机会。

Fucoidan is a polysaccharide found in brown algae (seaweed). ARC Medical Devices Inc. has developed and markets fucoidan extracted and purified from brown algae for post-surgical veterinary use to reduce adhesion development. This works very effectively, prompting a desire to develop the product for use in humans. The challenge to this, however, is that fucoidan is an extremely large molecule of heterogeneous composition, making it difficult to a) meet the higher standards of purity and homogeneity required of medical materials for use in human subjects and b) do so in quantities required for human trials. Our proposed solution is to harness naturally occurring enzymes found in marine bacteria and use these bio-processing enzymes to tailor the structure and size of fucoidan, and/or synthesize fucoidan fragments, such that the material is of more defined size and composition and can ultimately be obtained in large quantities of high purity. The pathway envisioned to achieve this has multiple steps, with the particular objective of this proposal being to achieve the initial and critical steps of generating the enzymatic tools required to enable the remodeling and/or synthesis of fucoidan. Successful completion of the project will result in a process to produce a novel, first in class medical device for the reduction of post-surgical adhesions in humans, which in turn will reduce pain, suffering, infertility and mortality in Canadian patients following common surgical procedures; reduce Canadian hospital stays, hospital re-admissions, and re-operations, which in turn will reduce healthcare costs for Canadian governments and taxpayers; and create scientific, manufacturing and sales jobs within Canada.